Skin patches for generic drug delivery.
Public company, workplace, funding, and market signals
Avro Life Science is a Waterloo-based clinical-stage biotechnology company building transdermal drug-delivery products that turn skin into a therapeutic vector. Its core product is a medicated sticker/skin patch platform for delivering antihistamines and other small molecules, originally aimed at children who struggle with pills and now extending to broader dermatology and transdermal therapy applications.
Primary product
Medicated stickers / transdermal skin patches for generic drug delivery
Founded
2016
Headquarters
Waterloo, Ontario, Canada
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Transdermal drug delivery / medical dermatology
Offices
Business model
Stage
early-stage
Total raised
$3M
Latest round
Venture Round · Jan 2021
Leadership
Co-Founder & CEO
Co-Founder
Vice President Research and Development
Public evidence suggests a small, research-heavy, mission-driven team. Hiring and profile snippets emphasize a fast-paced group of chemists, engineers, and biologists focused on redefining the skin's potential as a therapeutic vector.
Compensation
Public compensation signals are sparse. Indeed shows estimated pay for a Scientist at about C$65,650/year and a Biological Technician at about C$49,029/year, based on limited job/review data.
Pricing
Not publicly disclosed; likely a mix of product sales for patches and B2B pharma partnerships/licensing.
Differentiators
Technology
Customers
Competitors
Estimated revenue
≈$1M–$5M
PitchBook displayed an 'Out of Business' status for Avro Life Science on 2025-06-26, but this conflicts with the company's active official website and LinkedIn presence, so it should be treated cautiously as a potentially stale or erroneous data point.
SourceDailyDropout · Feb 2026
Recent profile describing Avro's TopiqIL and TransdermIL platforms, pipeline targets (psoriasis, atopic dermatitis, Parkinson's), team size, revenue estimate, and funding history.
GetLatka · Apr 2025
Revenue snapshot estimating about $1.2M in ARR, a $3.6M valuation, and an 8-person team as of 2026.
LifeScienceHistory.com · May 2024
Directory profile confirming the 2016 founding, Waterloo address, and Shak Lakhani as co-founder and CEO.
aVenture · Mar 2024
Research profile noting Waterloo HQ, 2016 founding, 18 employees, and $4.4M raised as of Jan. 1, 2021.
0 jobs at Avro Life Science
Check back later for new openings